Free Trial

Sartorius (SRTGR; NR, BBB S) {SRT GR Equity} 1Q24 Earnings

HEALTHCARE

Equities is struggling on a 1Q earnings miss - co has left FY guidance unchanged (firm numbers) saying recovery to come in 2H. We saw credit pricing scepticism on deleveraging (post acquisition/issuance) trading wide for ratings - guidance on leverage at just above 3x (vs. target 2-3x) by year end is reassuring but small FCF (even on 13% capex) leaves us at managements peril on any new acquisitions.

  • Equities taking it this morning on a 1Q earnings miss; revenue at €820m (c859m) & EBITDA at €234m (c€240m) at a margin of 28.6% (c28.4%) - guidance is unch at 30%+ for FY24.
  • Headline sales at -7.6% cc growth yoy includes +2% contribution from acquisitions. Its pointing to China weakness (sales -4.4%) as driver for miss. Guidance is unch at "mid to high single digit" growth with +1.5% contribution from acquisitions.
  • Operating cash flows were €45m - sharp fall from €202m in prior year - yet capex continued running at €135m or 15.7% of sales - its guiding to 13% for FY24.
  • Importantly for us leverage is at 4.4x now (from 5x) and its guiding to just above 3x by year-end - nearly at target 2-3x and (should) satisfy raters for now. It has added leverage guidance "excludes potential acquisitions" - an important aside for us there.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.